 |
The 130th Annual Meeting of APHA |
|
The 130th Annual Meeting of APHA |
Richard S Garfein, PhD, MPH, Division of HIV/AIDS Prevention, Epidemiology Branch, Centers for Disease Control and Prevention, 1600 Clifton Road, MS E-45, Atlanta, GA 30333, 404-639-6175, rlg6@cdc.gov
Session Abstract: In the early 90s, researchers recognized the need for early interventions to prevent the spread of bloodborne pathogens such as HIV, hepatitis B and hepatitis C viruses among injection drug users (IDUs). Since then, studies were conducted that attempted to assess the circumstances surrounding initiation of injection drug use, HIV-associated sexual and injection risk behaviors, social network factors, and sociodemographic characteristics of recently initiated IDUs. Given most IDUs do not enter drug treatment programs until they are many years into their addiction, investigators shifted from clinic-based to street-based strategies for recruiting recent-initiate IDUs as study participants. Furthermore, given that median age of initiation is around 19 years, age is a common eligibility criterion for screening out longer-term injectors.
In 1997-1999, The Centers for Disease Control and Prevention funded the Second Collaborative Injection Drug Users Study (CIDUS 2) to estimate the prevalence and incidence of HIV, HBV and HCV infections among new injectors and identify behaviors that increase their risk for these infections. This is the Nations largest multisite cohort study of new IDUs that recruited participants who were 18-30 year old or had been injecting for less than 5 years and included Baltimore, Chicago, Los Angeles, New Orleans, and two sites in New York (East Harlem and the Lower East Side). This session will include recent findings from this data set as well as two other studies that recruited from similar populations in Seattle, WA, and Russia. This session is intended to provide the audience with recent findings related to HIV risk among young and recently initiated IDUs.
Learning Objectives:
Keywords: HIV/AIDS, Intravenous Drug Use
Presenting author's disclosure statement:
I do not have any significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.